Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one corner while forgetting others, creating a gap and massive opportunity for rotation into some of these forgotten names that still carry greatly attractive fundamental profiles.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Eli Lilly (LLY) closed at $762.18 in the latest trading session, marking a -1.23% move from the prior day.
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Eli Lilly Comes Out As ADA Winner
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Favorable commercial trends for tirzepatide and a robust pipeline—including orforglipron and retatrutide—support Lilly's continued market dominance for the next 5-7 years.
